Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 Mg/850 Mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 Mg/850 Mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: Empagliflozin + Metformin hydrochloride 5 mg/850 mg film-coated tabletsDrug: Synjardy® 5 mg/850 mg film-coated tablets
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 64
- Registration Number
- NCT06766500
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
- Conditions
- Prader-Willi Syndrome
- Interventions
- Drug: RGH-706Drug: Placebo
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 39
- Registration Number
- NCT05322096
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Maimonides Medical Center, Brooklyn, New York, United States
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 473
- Registration Number
- NCT05087030
- Locations
- 🇵🇱
Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda, Lublin, Lubelskie, Poland
🇵🇱RCMed Oddział Warszawa, Warszawa, Poland
🇺🇸Global Health Research Center, Miami Lakes, Florida, United States
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 330
- Registration Number
- NCT03817502
- Locations
- 🇷🇺
SBHI of Moscow Region "Central Clinical Psychiatric Hospital", Moscow, Russian Federation
🇷🇺Clinical Psychiatry Hospital #1 of Nizhniy Novgorod, Nizhny Novgorod, Russian Federation
🇷🇺State Public Institution of Healthcare Leningrad Regional Psychoneurological Dispensary, Roshchino, Russian Federation
Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta
- Conditions
- Bioequivalence
- Interventions
- Drug: RGB-02 or Neulasta® (pegfilgrastim)
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 150
- Registration Number
- NCT03146988
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
Comparative Pharmacokinetic Trial of RGB-03 and MabThera
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Gedeon Richter Plc.
- Registration Number
- NCT02371096
A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Gedeon Richter Plc.
- Registration Number
- NCT02223416
- Locations
- 🇬🇧
Celerion (UK), Belfast, United Kingdom
Cariprazine: Comparison of Slow- and Immediate-release Forms
- Conditions
- Pharmacokinetic Profile
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Gedeon Richter Plc.
- Target Recruit Count
- 160
- Registration Number
- NCT02165098
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults
- Conditions
- Healthy Volunteers;Obese, Otherwise Healthy Volunteers
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Gedeon Richter Plc.
- Registration Number
- NCT02001584
- Locations
- 🇬🇧
Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom